Page last updated: 2024-08-21

psilocybin and Depression

psilocybin has been researched along with Depression in 90 studies

Research

Studies (90)

Timeframe	Studies, this research(%)	All Research%
pre-1990	4 (4.44)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	21 (23.33)	24.3611
2020's	65 (72.22)	2.80

Authors

Authors	Studies
Chen, WN; Hu, YR; Li, NX; Zhang, B	1
Bourzat, F; Harvey, K; Kryskow, P; Kuypers, KPC; Polito, V; Rootman, JM; Santos-Brault, E; Stamets, P; Walsh, Z	1
Agin-Liebes, G; Davis, AK	1
Breeksema, JJ; Schimmers, N; Schoevers, RA; Smith-Apeldoorn, SY; van den Brink, W; Veraart, J	1
O'Leary, K	1
Fejer, G; Hajkova, K; Kuchar, M; Lempe, P; Marschall, J; Prochazkova, L; van Elk, M	1
Gold, JA; Pearson, C; Siegel, J	1
Jordens, C; Miceli McMillan, R	1
Strous, JFM	1
de la Fuente Revenga, M; Elder, H; González-Maeso, J; Jaster, AM; Marsh, SA; Negus, SS	1
Carhart-Harris, R; Daws, RE; Erritzoe, D; Giribaldi, B; Nutt, D; Roseman, L; Sexton, JD; Timmermann, C; Wall, MB	1
Berens, N; Kim, SY	1
Willyard, C	1
Johannesdottir, A; Sigurdsson, E	1
Eisenstein, M	1
Cleare, AJ; Ko, K; Kopra, EI; Rucker, JJ	1
Dycha, N; Kurzepa, J; Nowak, EM; Psiuk, D; Samardakiewicz, M; Łopuszańska, U	1
Aaronson, ST; Alvarez, O; Arden, PC; Baker, A; Bennett, JC; Bird, C; Blom, RE; Brennan, C; Brusch, D; Burke, L; Campbell-Coker, K; Carhart-Harris, R; Cattell, J; Daniel, A; DeBattista, C; Dunlop, BW; Eisen, K; Feifel, D; Forbes, M; Goodwin, GM; Haumann, HM; Hellerstein, DJ; Hoppe, AI; Husain, MI; Jelen, LA; Kamphuis, J; Kawasaki, J; Kelly, JR; Key, RE; Kishon, R; Knatz Peck, S; Knight, G; Koolen, MHB; Lean, M; Licht, RW; Malievskaia, E; Maples-Keller, JL; Mars, J; Marwood, L; McElhiney, MC; Miller, TL; Mirow, A; Mistry, S; Mletzko-Crowe, T; Modlin, LN; Nielsen, RE; Nielson, EM; O'Keane, V; Offerhaus, SR; Páleníček, T; Printz, D; Rademaker, MC; Reinholdt, F; Repantis, D; Rucker, J; Rudow, S; Ruffell, S; Rush, AJ; Schoevers, RA; Seynaeve, M; Shao, S; Soares, JC; Somers, M; Stansfield, SC; Sterling, D; Strockis, A; Tsai, J; van Reemst, A; Visser, L; Wahba, M; Williams, S; Young, AH; Ywema, P; Zisook, S	1
Madras, BK	1
Carhart-Harris, R; Kaelen, M; Nutt, D; Roseman, L; Shukuroglou, M; Wall, M	1
Barber, G; Nemeroff, CB; Siegel, S	1
Gukasyan, N	1
Aaronson, ST; Alvarez, O; Atli, M; Bennett, JC; Croal, M; DeBattista, C; Dunlop, BW; Feifel, D; Goodwin, GM; Hellerstein, DJ; Husain, MI; Kelly, JR; Lennard-Jones, MR; Licht, RW; Malievskaia, E; Marwood, L; Mistry, S; Páleníček, T; Redjep, O; Repantis, D; Schoevers, RA; Septimus, B; Simmons, HJ; Soares, JC; Somers, M; Stansfield, SC; Stuart, JR; Tadley, HH; Thiara, NK; Tsai, J; Wahba, M; Williams, S; Winzer, RI; Young, AH; Young, MB; Zisook, S	1
Hieronymus, F; Østergaard, SD	2
Benyamina, A; Dervaux, A; Roméo, B	1
Courtet, P; Lengvenyte, A; Olié, E	1
Goodwin, GM; Hellerstein, DJ; Young, AH	1
Rucker, JJ	1
Julia Mertens, L	1
Agrawal, M; Emanuel, E; Richards, B; Richards, W; Roddy, K; Thambi, P	1
Carhart-Harris, RL; Ertl, N; Kaelen, M; Lam, C; Nutt, DJ; Roseman, L; Wall, MB	1
Carhart-Harris, RL; Erritzoe, D; Giribaldi, B; Nutt, DJ; Weiss, B	1
Jha, MK; Kamal, S; Radhakrishnan, R	1
Chakrabarty, T; DuBois, A; Keramatian, K; Saraf, G; Yatham, LN	1
Jawad, MY; Qasim, S; Shad, MU; Zaheer, Z	1
Brown, O	1
Haridy, R	1
D'Souza, DC; Pathania, S; Pittman, B; Safi-Aghdam, H; Skosnik, PD; Sloshower, J; Syed, S	1
Nogrady, B	1
Amit, M; Cohen, L; Ramondetta, LM; Yaniv, D	1
Carhart-Harris, R; Carlbring, P; Davis, AK; Erritzoe, D; Goldberg, SB; Griffiths, RR; Nutt, DJ; Simonsson, O	1
De Pieri, M; Kaiser, S; Kirschner, M; Langlest, F; Mallet, L; Perez, N; Sabé, M; Sentissi, O; Seragnoli, F; Solmi, M; Thorens, G; Zullino, D	1
Carlyle, D; Crowe, M; Lacey, C; Manuel, J	1
Müller, T	1
Chen-Li, DCJ; Fancy, F; Haikazian, S; Husain, MI; Johnson, DE; Levinta, A; Mansur, RB; McIntyre, RS; Rosenblat, JD	1
Reardon, S	1
Chruścicka-Smaga, B; Machaczka, A; Pilc, A; Szewczyk, B	1
Boudreau, E; Orlowski, K	1
Ahmed, H; Arshad, T; Mushahid, H	1
Germann, CB	1
Amada, N; Jungaberle, H; Klein, M; Lea, T; Schecke, H	1
Goldberg, SB; Hutson, PR; Nicholas, CR; Pace, BT; Raison, CL	1
Jones, TK; Lippmann, S	1
Mathuru, AS; Vitkauskas, M	1
Reynolds, CF	1
de Manincor, M; Galvão-Coelho, NL; Gonzalez, M; Marx, W; Perkins, D; Sarris, J; Sinclair, J	1
Tullis, P	1
Bouso, JC; Dos Santos, RG; Hallak, JEC; Ona, G	1
Cole, AB; Hesselgrave, N; Thompson, SM; Troppoli, TA; Wulff, AB	1
Jordan, I	1
Bei, B; Wiley, JF	1
Gründer, G; Mertens, L	1
Blemings, A; Carhart-Harris, R; Nutt, DJ	1
Bayat, M	1
Bolstridge, M; Carhart-Harris, RL; Curran, HV; Demetriou, L; Kaelen, M; Leech, R; McGonigle, J; Murphy, K; Nutt, DJ; Pannekoek, JN; Roseman, L; Tanner, M; Wall, MB	1
Johnson, MI; Whelan, A	1
Flanagan, TW; Nichols, CD	1
Ross, S	1
Andreassen, OA; Kvam, TM; Stewart, LH	1
Anderson, T; Dinh-Williams, LA; Farb, NAS; Hapke, E; Hui, K; Petranker, R; Rosenbaum, D; Weissman, CR	1
Kuypers, KPC	1
Christiansen, SL; Elfving, B; Højgaard, K; Jefsen, O; Müller, HK; Nutt, DJ; Wegener, G	1
Bosch, OG; Kraehenmann, R; Pokorny, T; Preller, KH; Scheidegger, M; Seifritz, E; Vollenweider, FX	1
Hawkes, N	1
Cowen, P	1
Hendrie, C; Pickles, A	1
Cohen, AF; Dijkstra, FM; Jacobs, GE	1
de Veen, BT; Homberg, JR; Schellekens, AF; Verheij, MM	1
Barrett, FS; Bradstreet, MP; Griffiths, RR; Johnson, MW; Leoutsakos, JS	1
Nutt, D	1
Agin-Liebes, G; Babb, J; Belser, A; Bossis, A; Cohen, B; Corby, P; Guss, J; Kalliontzi, K; Malone, T; Mennenga, SE; Ross, S; Schmidt, BL; Su, Z	1
Carducci, MA; Cosimano, MP; Griffiths, RR; Johnson, MW; Klinedinst, MA; Richards, BD; Richards, WA; Umbricht, A	1
McCorvy, JD; Olsen, RH; Roth, BL	1
Johnson, MW; Nichols, CD; Nichols, DE	1
JAROS, O; KOVARIK, J; SERCL, M	1
CANCRINI, L; D AGOSTINO, E; REDA, GC; VELLA, G	1
Kochansky, GE; Lieff, J; Salzman, C; Shader, RI	1
Rysánek, K	1

Reviews

26 review(s) available for psilocybin and Depression

Article	Year
Dose effect of psilocybin on primary and secondary depression: a preliminary systematic review and meta-analysis. Journal of affective disorders, 2022, 01-01, Volume: 296 Topics: Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Psilocybin	2022
Psychedelics for the treatment of depression, anxiety, and existential distress in patients with a terminal illness: a systematic review. Psychopharmacology, 2022, Volume: 239, Issue:1 Topics: Anxiety; Depression; Hallucinogens; Humans; Psilocybin; Quality of Life	2022
Psilocybin-assisted psychotherapy for depression: Emerging research on a psychedelic compound with a rich history. Journal of the neurological sciences, 2022, Mar-15, Volume: 434 Topics: Depression; Depressive Disorder, Major; Hallucinogens; Humans; Psilocybin; Psychotherapy	2022
[The use of psilocybin for treatment-resistant depression]. Laeknabladid, 2022, Volume: 108, Issue:9 Topics: Antidepressive Agents; Depression; Depressive Disorder, Treatment-Resistant; Hallucinogens; Humans; Psilocybin; Randomized Controlled Trials as Topic	2022
Psychedelic therapy for depressive symptoms: A systematic review and meta-analysis. Journal of affective disorders, 2023, 02-01, Volume: 322 Topics: Depression; Depressive Disorder, Major; Hallucinogens; Humans; Lysergic Acid Diethylamide; Psilocybin	2023
Esketamine and Psilocybin-The Comparison of Two Mind-Altering Agents in Depression Treatment: Systematic Review. International journal of molecular sciences, 2022, Sep-28, Volume: 23, Issue:19 Topics: Antidepressive Agents; Depression; Depressive Disorder, Treatment-Resistant; Hallucinogens; Humans; Ketamine; Psilocybin	2022
MMW Fortschritte der Medizin, 2023, Volume: 165, Issue:7 Topics: Depression; Humans; Psilocybin	2023
Role of Psychedelics in Treatment-Resistant Depression. The Psychiatric clinics of North America, 2023, Volume: 46, Issue:2 Topics: Depression; Depressive Disorder, Treatment-Resistant; Hallucinogens; Humans; Ketamine; Psilocybin	2023
New Pharmacologic Approaches to the Treatment of Bipolar Depression. Drugs, 2023, Volume: 83, Issue:10 Topics: Antidepressive Agents; Bipolar Disorder; Depression; Humans; Ketamine; Psilocybin; Randomized Controlled Trials as Topic; Treatment Outcome	2023
Neurobiological Correlates of Psilocybin Response in Depression. The primary care companion for CNS disorders, 2023, May-23, Volume: 25, Issue:3 Topics: Antidepressive Agents; Brain; Depression; Humans; Psilocybin; Psychotherapy; Randomized Controlled Trials as Topic	2023
Assessing the risk of symptom worsening in psilocybin-assisted therapy for depression: A systematic review and individual participant data meta-analysis. Psychiatry research, 2023, Volume: 327 Topics: Depression; Escitalopram; Hallucinogens; Humans; Psilocybin; Sample Size; Symptom Flare Up	2023
Psilocybin-assisted therapy for depression: A systematic review and dose-response meta-analysis of human studies. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 2023, Volume: 76 Topics: Adult; Antidepressive Agents; Depression; Humans; Psilocybin; Psychotic Disorders; Randomized Controlled Trials as Topic	2023
Psilocybin-assisted therapy for depression: A systematic review and meta-analysis. Psychiatry research, 2023, Volume: 329 Topics: Antidepressive Agents; Depression; Depressive Disorder, Major; Hallucinogens; Humans; Psilocybin; Psychotherapy	2023
Interaction of hallucinogenic rapid-acting antidepressants with mGlu2/3 receptor ligands as a window for more effective therapies. Pharmacological reports : PR, 2023, Volume: 75, Issue:6 Topics: Antidepressive Agents; Depression; Hallucinogens; Ketamine; Psilocybin; Receptors, Metabotropic Glutamate; Scopolamine	2023
The experimental effects of psilocybin on symptoms of anxiety and depression: A meta-analysis. Psychiatry research, 2020, Volume: 284 Topics: Anxiety; Depression; Female; Humans; Male; Psilocybin; Randomized Controlled Trials as Topic; Treatment Outcome	2020
Total Recall: Lateral Habenula and Psychedelics in the Study of Depression and Comorbid Brain Disorders. International journal of molecular sciences, 2020, Sep-07, Volume: 21, Issue:18 Topics: Brain Diseases; Comorbidity; Depression; Depressive Disorder; Habenula; Hallucinogens; Humans; Psilocybin; Serotonergic Neurons	2020
Classic serotonergic psychedelics for mood and depressive symptoms: a meta-analysis of mood disorder patients and healthy participants. Psychopharmacology, 2021, Volume: 238, Issue:2 Topics: Affect; Banisteriopsis; Depression; Depressive Disorder, Major; Double-Blind Method; Hallucinogens; Healthy Volunteers; Humans; Lysergic Acid Diethylamide; Mood Disorders; Psilocybin; Randomized Controlled Trials as Topic; Serotonin Receptor Agonists; Treatment Outcome	2021
Psychedelic Medicines in Major Depression: Progress and Future Challenges. Advances in experimental medicine and biology, 2021, Volume: 1305 Topics: Depression; Depressive Disorder, Major; Hallucinogens; Humans; Psilocybin; Psychiatry	2021
[Classic psychedelic drugs and their potential therapeutic effect]. Ugeskrift for laeger, 2017, Sep-11, Volume: 179, Issue:37 Topics: Anti-Anxiety Agents; Antidepressive Agents; Anxiety; Cluster Headache; Depression; Hallucinogens; Humans; Lysergic Acid Diethylamide; Obsessive-Compulsive Disorder; Psilocybin; Receptor, Serotonin, 5-HT2A; Substance-Related Disorders	2017
Lysergic acid diethylamide and psilocybin for the management of patients with persistent pain: a potential role? Pain management, 2018, Volume: 8, Issue:3 Topics: Anxiety; Chronic Pain; Depression; Humans; Lysergic Acid Diethylamide; Pain; Psilocybin; Serotonin Receptor Agonists; Treatment Outcome	2018
Therapeutic use of classic psychedelics to treat cancer-related psychiatric distress. International review of psychiatry (Abingdon, England), 2018, Volume: 30, Issue:4 Topics: Anxiety; Depression; Hallucinogens; Humans; Lysergic Acid Diethylamide; Neoplasms; Psilocybin; Serotonin Antagonists; Stress, Psychological	2018
Psychedelic drugs in the treatment of anxiety, depression and addiction. Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke, 2018, 11-13, Volume: 138, Issue:18 Topics: Anxiety; Anxiety Disorders; Depression; Depressive Disorder; Hallucinogens; Humans; Lysergic Acid Diethylamide; Obsessive-Compulsive Disorder; Psilocybin; Substance-Related Disorders	2018
Psilocybin for treating substance use disorders? Expert review of neurotherapeutics, 2017, Volume: 17, Issue:2 Topics: Depression; Emotions; Hallucinogens; Humans; Psilocybin; Substance-Related Disorders	2017
Psychedelics as Medicines: An Emerging New Paradigm. Clinical pharmacology and therapeutics, 2017, Volume: 101, Issue:2 Topics: Anxiety; Brain; Clinical Trials as Topic; Depression; Dose-Response Relationship, Drug; Hallucinogens; Humans; Inflammation; Inflammation Mediators; Lysergic Acid Diethylamide; Mental Disorders; Mind-Body Therapies; Obsessive-Compulsive Disorder; Psilocybin; Psychotherapy; Receptor, Serotonin, 5-HT2A; Serotonin 5-HT2 Receptor Agonists; Severity of Illness Index; Substance-Related Disorders	2017
[CLINICAL AND PSYCHOPATHOLOGICAL STUDY OF PSILOCYBIN]. Rivista sperimentale di freniatria e medicina legale delle alienazioni mentali, 1964, Mar-31, Volume: 88 Topics: Antisocial Personality Disorder; Asthenia; Blood Pressure; Consciousness; Depression; Depressive Disorder; Electroencephalography; Hallucinations; Hallucinogens; Hearing Disorders; Indoles; Mental Disorders; Mental Processes; Movement Disorders; Nausea; Pharmacology; Psilocybin; Psychopathology; Salivary Glands; Sweating; Toxicology; Vestibule, Labyrinth; Visual Perception	1964
[Relation of monoamines to mental disorders]. Activitas nervosa superior, 1970, Volume: 12, Issue:2 Topics: Amines; Animals; Bipolar Disorder; Catecholamines; Central Nervous System; Depression; Dihydroxyphenylalanine; Dopamine; Epinephrine; Hallucinogens; Humans; Lysergic Acid Diethylamide; Mental Disorders; Methylation; Monoamine Oxidase Inhibitors; Phenethylamines; Psilocybin; Reserpine; Schizophrenia; Serotonin; Tryptamines	1970

Trials

11 trial(s) available for psilocybin and Depression

Article	Year
Psilocybin microdosing does not affect emotion-related symptoms and processing: A preregistered field and lab-based study. Journal of psychopharmacology (Oxford, England), 2022, Volume: 36, Issue:1 Topics: Adult; Anxiety; Cross-Over Studies; Depression; Dose-Response Relationship, Drug; Double-Blind Method; Emotions; Female; Hallucinogens; Humans; Male; Middle Aged; Psilocybin; Surveys and Questionnaires; Young Adult	2022
[Psilocybin compared with escitalopram for depression]. Nederlands tijdschrift voor geneeskunde, 2022, 01-17, Volume: 166 Topics: Depression; Escitalopram; Hallucinogens; Humans; Psilocybin; Psychiatry	2022
Increased global integration in the brain after psilocybin therapy for depression. Nature medicine, 2022, Volume: 28, Issue:4 Topics: Antidepressive Agents; Brain; Depression; Depressive Disorder, Major; Double-Blind Method; Escitalopram; Hallucinogens; Humans; Psilocybin	2022
Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. The New England journal of medicine, 2022, 11-03, Volume: 387, Issue:18 Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Double-Blind Method; Humans; Psilocybin; Treatment Outcome	2022
Single-dose psilocybin for a treatment-resistant episode of major depression: Impact on patient-reported depression severity, anxiety, function, and quality of life. Journal of affective disorders, 2023, 04-14, Volume: 327 Topics: Anxiety; Depression; Depressive Disorder, Major; Humans; Patient Reported Outcome Measures; Psilocybin; Quality of Life	2023
Increased low-frequency brain responses to music after psilocybin therapy for depression. Journal of affective disorders, 2023, 07-15, Volume: 333 Topics: Brain; Brain Mapping; Depression; Hallucinogens; Humans; Magnetic Resonance Imaging; Music; Psilocybin	2023
Sub-acute effects of psilocybin on EEG correlates of neural plasticity in major depression: Relationship to symptoms. Journal of psychopharmacology (Oxford, England), 2023, Volume: 37, Issue:7 Topics: Antidepressive Agents; Depression; Depressive Disorder, Major; Electroencephalography; Hallucinogens; Humans; Neuronal Plasticity; Psilocybin	2023
Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms. Scientific reports, 2017, 10-13, Volume: 7, Issue:1 Topics: Adult; Brain; Depression; Female; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Psilocybin	2017
Psilocybin-Induced Decrease in Amygdala Reactivity Correlates with Enhanced Positive Mood in Healthy Volunteers. Biological psychiatry, 2015, Oct-15, Volume: 78, Issue:8 Topics: Adult; Affect; Amygdala; Cross-Over Studies; Depression; Double-Blind Method; Female; Hallucinogens; Healthy Volunteers; Humans; Magnetic Resonance Imaging; Male; Psilocybin; Psychiatric Status Rating Scales; Young Adult	2015
Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. Journal of psychopharmacology (Oxford, England), 2016, Volume: 30, Issue:12 Topics: Adult; Aged; Anxiety; Cross-Over Studies; Depression; Double-Blind Method; Female; Hallucinogens; Humans; Male; Middle Aged; Neoplasms; Psilocybin; Psychotherapy; Quality of Life; Surveys and Questionnaires; Young Adult	2016
Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. Journal of psychopharmacology (Oxford, England), 2016, Volume: 30, Issue:12 Topics: Anxiety; Attitude; Cross-Over Studies; Depression; Double-Blind Method; Female; Follow-Up Studies; Hallucinogens; Humans; Male; Middle Aged; Neoplasms; Psilocybin; Quality of Life; Surveys and Questionnaires	2016

Other Studies

53 other study(ies) available for psilocybin and Depression

Article	Year
Adults who microdose psychedelics report health related motivations and lower levels of anxiety and depression compared to non-microdosers. Scientific reports, 2021, 11-18, Volume: 11, Issue:1 Topics: Adolescent; Adult; Anxiety; Cognition; Cross-Sectional Studies; Depression; Female; Hallucinogens; Humans; International Cooperation; Lysergic Acid Diethylamide; Male; Mental Health; Middle Aged; Motivation; Psilocybin; Surveys and Questionnaires; Young Adult	2021
Psilocybin for the Treatment of Depression: A Promising New Pharmacotherapy Approach. Current topics in behavioral neurosciences, 2022, Volume: 56 Topics: Depression; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Hallucinogens; Humans; Psilocybin	2022
Psychiatry goes psychedelic. Nature medicine, 2021, Volume: 27, Issue:12 Topics: Clinical Trials, Phase II as Topic; Depression; Escitalopram; Hallucinogens; Humans; Psilocybin; Psychiatry; Randomized Controlled Trials as Topic; Selective Serotonin Reuptake Inhibitors	2021
Psychedelic-assisted psychotherapy for the treatment of major depression: a synthesis of phenomenological explanations. Medicine, health care, and philosophy, 2022, Volume: 25, Issue:2 Topics: Depression; Depressive Disorder, Major; Hallucinogens; Humans; Psilocybin; Psychotherapy	2022
Effects of the 5-HT Psychopharmacology, 2022, Volume: 239, Issue:6 Topics: Animals; Depression; Fluorobenzenes; Hallucinogens; Lysergic Acid Diethylamide; Mescaline; Mice; Phenethylamines; Piperidines; Psilocybin; Rats; Receptor, Serotonin, 5-HT2A; Rodentia; Self Stimulation; Serotonin; Tryptamines	2022
Psilocybin increases brain network integration in patients with depression. Nature medicine, 2022, Volume: 28, Issue:4 Topics: Brain; Depression; Hallucinogens; Humans; Psilocybin	2022
Rapid-Response Treatments for Depression and Requests for Physician-Assisted Death: An Ethical Analysis. The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, 2022, Volume: 30, Issue:11 Topics: Depression; Ethical Analysis; Female; Humans; Ketamine; Physicians; Psilocybin; Suicide, Assisted	2022
Psychedelic drugs take on depression. Nature, 2022, Volume: 608, Issue:7924 Topics: Depression; Hallucinogens; Lysergic Acid Diethylamide; Psilocybin	2022
The psychedelic escape from depression. Nature, 2022, Volume: 609, Issue:7929 Topics: Depression; Hallucinogens; Humans; Psilocybin	2022
Psilocybin in Treatment-Resistant Depression. The New England journal of medicine, 2022, 11-03, Volume: 387, Issue:18 Topics: Depression; Depressive Disorder, Treatment-Resistant; Hallucinogens; Humans; Psilocybin	2022
Changes in music-evoked emotion and ventral striatal functional connectivity after psilocybin therapy for depression. Journal of psychopharmacology (Oxford, England), 2023, Volume: 37, Issue:1 Topics: Anhedonia; Depression; Emotions; Hallucinogens; Humans; Magnetic Resonance Imaging; Music; Psilocybin	2023
A Case of Prolonged Mania, Psychosis, and Severe Depression After Psilocybin Use: Implications of Increased Psychedelic Drug Availability. The American journal of psychiatry, 2022, 12-01, Volume: 179, Issue:12 Topics: Depression; Depressive Disorder, Major; Hallucinogens; Humans; Mania; Psilocybin; Psychotic Disorders	2022
On blinding and suicide risk in a recent trial of psilocybin-assisted therapy for treatment-resistant depression. Med (New York, N.Y.), 2023, 01-13, Volume: 4, Issue:1 Topics: Depression; Depressive Disorder, Treatment-Resistant; Hallucinogens; Humans; Psilocybin; Suicide	2023
Psilocybin for Treatment-Resistant Depression. The New England journal of medicine, 2023, Feb-23, Volume: 388, Issue:8 Topics: Depression; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Hallucinogens; Humans; Psilocybin	2023
Psilocybin for Treatment-Resistant Depression. The New England journal of medicine, 2023, Feb-23, Volume: 388, Issue:8 Topics: Depression; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Hallucinogens; Humans; Psilocybin	2023
Psilocybin for Treatment-Resistant Depression. The New England journal of medicine, 2023, Feb-23, Volume: 388, Issue:8 Topics: Depression; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Hallucinogens; Humans; Psilocybin	2023
Psilocybin for Treatment-Resistant Depression. Reply. The New England journal of medicine, 2023, Feb-23, Volume: 388, Issue:8 Topics: Depression; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Hallucinogens; Humans; Psilocybin	2023
Psilocybin therapy for depression. A good trip? Journal of mental health (Abingdon, England), 2023, Volume: 32, Issue:1 Topics: Depression; Humans; Psilocybin	2023
Assessment of Psilocybin Therapy for Patients With Cancer and Major Depression Disorder. JAMA oncology, 2023, Jun-01, Volume: 9, Issue:6 Topics: Depression; Depressive Disorder, Major; Humans; Neoplasms; Patients; Psilocybin	2023
A critical evaluation of QIDS-SR-16 using data from a trial of psilocybin therapy versus escitalopram treatment for depression. Journal of psychopharmacology (Oxford, England), 2023, Volume: 37, Issue:7 Topics: Clinical Trials as Topic; Depression; Depressive Disorder, Major; Escitalopram; Humans; Psilocybin; Psychiatric Status Rating Scales; Reproducibility of Results	2023
Letter to the editor on "Increased low-frequency brain responses to music after psilocybin therapy for depression". Journal of affective disorders, 2023, 10-01, Volume: 338 Topics: Brain; Depression; Hallucinogens; Humans; Music; Psilocybin	2023
Australia to prescribe MDMA and psilocybin for PTSD and depression in world first. Nature, 2023, Volume: 619, Issue:7969 Topics: Australia; Depression; Drug Approval; Humans; N-Methyl-3,4-methylenedioxyamphetamine; Psilocybin; Stress Disorders, Post-Traumatic; Time Factors	2023
Australia's approval of MDMA and psilocybin for PTSD and depression is premature, say critics. BMJ (Clinical research ed.), 2023, 07-11, Volume: 382 Topics: Australia; Depression; Humans; N-Methyl-3,4-methylenedioxyamphetamine; Psilocybin; Stress Disorders, Post-Traumatic	2023
Psilocybin-assisted psychotherapy for cancer-related anxiety and depression. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2023, 08-07, Volume: 33, Issue:8 Topics: Anxiety; Depression; Humans; Neoplasms; Psilocybin; Psychotherapy	2023
Psilocybin-assisted psychotherapy for treatment-resistant depression: Which psychotherapy? International journal of mental health nursing, 2023, Volume: 32, Issue:6 Topics: Depression; Emotions; Hallucinogens; Humans; Psilocybin; Psychotherapy	2023
MMW Fortschritte der Medizin, 2023, Volume: 165, Issue:17 Topics: Depression; Humans; Psilocybin	2023
Psychedelic treatments are speeding towards approval - but no one knows how they work. Nature, 2023, Volume: 623, Issue:7985 Topics: Depression; Hallucinogens; Humans; N-Methyl-3,4-methylenedioxyamphetamine; Psilocybin; Psychological Trauma; Uncertainty	2023
Psilocybin therapy to reduce depression following a terminal diagnosis. JAAPA : official journal of the American Academy of Physician Assistants, 2023, 12-01, Volume: 36, Issue:12 Topics: Anxiety; Depression; Humans; Psilocybin	2023
UNCOVERING THE UNTAPPED POTENTIAL OF PSILOCYBIN THERAPY IN ALLEVIATING CANCER-RELATED DEPRESSION: AN URGENT CALL TO RE-EVALUATE TREATMENT STRATEGIES. Psychiatria Danubina, 2023,Winter, Volume: 35, Issue:4 Topics: Depression; Hallucinogens; Humans; Neoplasms; Psilocybin	2023
The Psilocybin-Telomere Hypothesis: An empirically falsifiable prediction concerning the beneficial neuropsychopharmacological effects of psilocybin on genetic aging. Medical hypotheses, 2020, Volume: 134 Topics: Aging; Aging, Premature; Animals; Anxiety; Brain-Derived Neurotrophic Factor; Consciousness; Depression; Disease Models, Animal; DNA Methylation; Endocrine System; Humans; Models, Genetic; Models, Psychological; Neurotransmitter Agents; Oxidative Stress; Personality; Psilocybin; Psychotropic Drugs; Research Design; Serotonin Plasma Membrane Transport Proteins; Stress, Psychological; Telomere Shortening	2020
Microdosing psychedelics: Motivations, subjective effects and harm reduction. The International journal on drug policy, 2020, Volume: 75 Topics: Adult; Anxiety; Depression; Dose-Response Relationship, Drug; Female; Hallucinogens; Harm Reduction; Humans; Lysergic Acid Diethylamide; Male; Mental Health; Middle Aged; Motivation; Psilocybin; Substance-Related Disorders; Surveys and Questionnaires; Young Adult	2020
Psilocybin Can Diminish Depression. The primary care companion for CNS disorders, 2020, Sep-03, Volume: 22, Issue:5 Topics: Anxiety; Depression; Hallucinogens; Humans; Psilocybin	2020
Psilocybin-Assisted Supportive Psychotherapy in the Treatment of Major Depression-Quo Vadis? JAMA psychiatry, 2021, 05-01, Volume: 78, Issue:5 Topics: Depression; Depressive Disorder, Major; Humans; Psilocybin; Psychotherapy	2021
How ecstasy and psilocybin are shaking up psychiatry. Nature, 2021, Volume: 589, Issue:7843 Topics: Animals; Certification; Clinical Trials as Topic; Depression; Depressive Disorder, Treatment-Resistant; Drug Prescriptions; Efficiency; Humans; Lysergic Acid Diethylamide; N-Methyl-3,4-methylenedioxyamphetamine; N,N-Dimethyltryptamine; Neuronal Plasticity; Niacin; Psilocybin; Psychiatry; Psychotherapy; Rumination, Cognitive; Selective Serotonin Reuptake Inhibitors; Serotonin; Stress Disorders, Post-Traumatic	2021
Harnessing psilocybin: antidepressant-like behavioral and synaptic actions of psilocybin are independent of 5-HT2R activation in mice. Proceedings of the National Academy of Sciences of the United States of America, 2021, 04-27, Volume: 118, Issue:17 Topics: Animals; Depression; Drug Evaluation, Preclinical; Hallucinogens; Hippocampus; Ketanserin; Male; Mice, Inbred C57BL; Psilocybin; Receptors, Serotonin, 5-HT2; Serotonin 5-HT2 Receptor Agonists; Stress, Psychological	2021
Psilocybin for Depression. The New England journal of medicine, 2021, Aug-26, Volume: 385, Issue:9 Topics: Anxiety; Depression; Humans; Psilocybin	2021
Psilocybin for Depression. The New England journal of medicine, 2021, Aug-26, Volume: 385, Issue:9 Topics: Anxiety; Depression; Humans; Psilocybin	2021
Psilocybin for Depression. The New England journal of medicine, 2021, 08-26, Volume: 385, Issue:9 Topics: Anxiety; Depression; Humans; Psilocybin	2021
Psilocybin for Depression. The New England journal of medicine, 2021, Aug-26, Volume: 385, Issue:9 Topics: Anxiety; Depression; Humans; Psilocybin	2021
Psilocybin for Depression. Reply. The New England journal of medicine, 2021, 08-26, Volume: 385, Issue:9 Topics: Anxiety; Depression; Humans; Psilocybin	2021
Psychedelics as anti-inflammatory agents. International review of psychiatry (Abingdon, England), 2018, Volume: 30, Issue:4 Topics: Amphetamines; Animals; Anti-Inflammatory Agents; Anxiety; Behavior, Animal; Depression; Hallucinogens; Humans; Obsessive-Compulsive Disorder; Psilocybin; Receptor, Serotonin, 5-HT2A	2018
Microdosing psychedelics: personality, mental health, and creativity differences in microdosers. Psychopharmacology, 2019, Volume: 236, Issue:2 Topics: Adult; Anxiety; Creativity; Depression; Dose-Response Relationship, Drug; Emotions; Female; Hallucinogens; Humans; Lysergic Acid Diethylamide; Male; Mental Health; Perception; Personality; Psilocybin; Surveys and Questionnaires	2019
Psychedelic medicine: The biology underlying the persisting psychedelic effects. Medical hypotheses, 2019, Volume: 125 Topics: Animals; Banisteriopsis; Cognition; Consciousness; Depression; Diet; Hallucinogens; Humans; Life Style; Lysergic Acid Diethylamide; Microbiota; Models, Biological; Psilocybin; Sleep	2019
Psilocybin lacks antidepressant-like effect in the Flinders Sensitive Line rat. Acta neuropsychiatrica, 2019, Volume: 31, Issue:4 Topics: Animals; Antidepressive Agents; Behavior, Animal; Depression; Disease Models, Animal; Male; Motor Activity; Psilocybin; Rats	2019
Sixty seconds on . . . psilocybin. BMJ (Clinical research ed.), 2016, 05-18, Volume: 353 Topics: Depression; Dose-Response Relationship, Drug; Hallucinogens; Humans; London; Psilocybin	2016
Altered states: psilocybin for treatment-resistant depression. The lancet. Psychiatry, 2016, Volume: 3, Issue:7 Topics: Depression; Depressive Disorder, Treatment-Resistant; Feasibility Studies; Hallucinogens; Humans; Psilocybin	2016
Psilocybin: panacea or placebo? The lancet. Psychiatry, 2016, Volume: 3, Issue:9 Topics: Depression; Depressive Disorder, Treatment-Resistant; Feasibility Studies; Hallucinogens; Humans; Psilocybin	2016
Question-based Drug Development for psilocybin. The lancet. Psychiatry, 2016, Volume: 3, Issue:9 Topics: Depression; Drug Development; Feasibility Studies; Hallucinogens; Psilocybin	2016
The Challenging Experience Questionnaire: Characterization of challenging experiences with psilocybin mushrooms. Journal of psychopharmacology (Oxford, England), 2016, Volume: 30, Issue:12 Topics: Adult; Affect; Agaricales; Anxiety; Depression; Emotions; Female; Hallucinogens; Humans; Male; Psilocybin; Surveys and Questionnaires	2016
Psilocybin for anxiety and depression in cancer care? Lessons from the past and prospects for the future. Journal of psychopharmacology (Oxford, England), 2016, Volume: 30, Issue:12 Topics: Anxiety; Depression; Hallucinogens; Humans; Neoplasms; Psilocybin	2016
Psilocybin for depression and anxiety associated with life-threatening illnesses. Journal of psychopharmacology (Oxford, England), 2016, Volume: 30, Issue:12 Topics: Anxiety; Depression; Depressive Disorder; Hallucinogens; Humans; Psilocybin	2016
[Clinical experiences with psilocybin (CY 39 Sandoz)]. Psychiatria et neurologia, 1961, Volume: 142 Topics: Depression; Depressive Disorder; Indoles; Neurotic Disorders; Psilocybin	1961
The psychology of hallucinogenic drug discontinuers. The American journal of psychiatry, 1972, Volume: 129, Issue:6 Topics: Adult; Anxiety; Depression; Female; Gambling; Hallucinogens; Humans; Lysergic Acid Diethylamide; Male; Mental Disorders; Mescaline; MMPI; Personality; Psilocybin; Psychological Tests; Substance-Related Disorders	1972